Published in Medical Letter on the CDC and FDA, December 3rd, 2006
This orphan medicinal product status grants CytRx market exclusivity in the European Union (E.U.) for 10 years in the event that arimoclomol receives marketing approval, and provides for incentives such as reduced fees for protocol assistance and scientific advice.
"We appreciate the European Commission's recognition of arimoclomol as a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.